Nasdaq Minimum Bid Price Noncompliance (new) — Company received Nov 2025 notice for failing to maintain $1.00 bid price; must cure by May 25, 2026 or face delisting.
Material Weakness (improved) — Remediated complex transactions weakness but IT and purchase-to-pay weaknesses persist from prior year.

NASDAQ: AKTX Akari Therapeutics Plc 10-K

Akari narrows to ADC platform, writes off PHP-303, extends cash to April 2026 via dilutive raises

Filed March 30, 2026 · Period ending December 31, 2025 · Compared to 10-K Apr 15, 2025 · ~2 min read

5 material changes detected in this filing.

Create a free account to read the full summary — it takes 30 seconds.

Partner

Trade AKTX commission-free

Open an account, get a free stock.

Investing involves risk. Free stock terms apply.

Generated by AI · Jun 4, 2026 1:29 AM